If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.
Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...
Medpage Today on MSN6d
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney DiseaseThe dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
A team of researchers, led by one of Indian origin, has found that a drug recently approved by the US Food and Drug ...
Sotagliflozin belongs to a class of medications called gliflozins that help lower blood sugar levels by preventing the ...
News Medical on MSN6d
Sotagliflozin could be used to reduce the risk of deadly cardiovascular events, trial showsSotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
The Brighterside of News on MSN1d
First of its kind drug significantly reduces heart attacks and strokesA recently approved drug has shown promise in reducing heart attacks and strokes in patients with type 2 diabetes and kidney disease. This medication, a sodium-glucose cotransporter (SGLT) inhibitor, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback